{"schema_version":"secwatch.filing_event.v1","accession":"0001737287-23-000051","form_type":"8-K","ticker":"ALLO","cik":"0001737287","company_name":"Allogene Therapeutics, Inc.","filed_at":"2023-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.301288+00:00","generated_at":"2026-06-16T01:21:20.901558+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Allogene reports Q1 net loss $98.7M, cash $514M; clinical progress in ALLO-501A and ALLO-316","bullets":["Net loss $98.7M ($0.68/share); R&D $80.2M, G&A $18.9M; cash $514M as of March 31, 2023.","Phase 2 ALPHA2 trial enrollment ongoing for ALLO-501A in R/R large B cell lymphoma; expects enrollment completion 1H 2024.","Initiated EXPAND trial to support licensure of ALLO-647; randomized ~70 patients to FCA90 vs FC alone before ALLO-501A.","Interim Phase 1 data on ALLO-316 in RCC: 3 of 10 CD70+ patients achieved partial response; disease control rate 100% in CD70+ subset.","Appointed Timothy Moore as Chief Technical Officer; fiscal 2023 guidance: cash burn ~$230M, GAAP OpEx ~$340M, runway into Q2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001737287-23-000051","json":"https://secwatch.observer/filing/0001737287-23-000051.json","markdown":"https://secwatch.observer/filing/0001737287-23-000051.md","text":"https://secwatch.observer/filing/0001737287-23-000051.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737287/000173728723000051/0001737287-23-000051-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737287/000173728723000051/allo-20230503.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T01:21:20.901558+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2ff2e968b1a24d027c5e5371b651ac3985c2ec56","claim":"Allogene Therapeutics, Inc. reported financial results for the quarter ended March 31, 2023.","evidence_excerpt":"On May 3, 2023, Allogene Therapeutics, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended March 31, 2023 in the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1737287/000173728723000051/0001737287-23-000051-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}